trial

An Open Trial of Cysteamine Treatment in Schizophrenia

NCTId NCT01139125
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Terminated
Enrollment 3 (actual)
Sponsored by Augusta University
Primary completion 2012-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Terminated
Enrollment
3 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2009-09
Primary completion
2012-06
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
(Cystagon) Cysteamine Bitartrate

Sponsors

Augusta UniversityLead Sponsor

Investigators

1
Peter Handest, MD, Ph.d.Principal Investigator

Sites

2 total
Augusta, United StatesAugusta, United States

Facts & assertions

4 sourced
Enrollment
3
Phase
NA
Primary Completion Date
2012-06
Status
TERMINATED
relationships
The graph out of here
drug
(Cystagon) Cysteamine Bitartrate
drug
lead_sponsor
Augusta University
company
indication
Schizophrenia
indication
Schizoaffective
indication
Schizophrenia
indication
investigator
Peter Handest, MD, Ph.d.
person